retatrutide type 2 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase The Science Behind Retatrutide: A

Working on that third receptor may provide added effects for appetite inhibition and insulin sensitivity. In other words, it may help people lose more weight faster

After SELECT, the debate ended

Nonsteroidal mineralocorticoid receptor antagonist Finerenone has recently been investigated in people with DKD (defined as an albumin to creatinine ratio of at least 3 mg/mmol and eGFR of 25 to 75 mL/min/1.73 m 2 ) who were treated with reninangiotensin system inhibitors

Mechanism of Action Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors

For many individuals, weight loss has been a life-long battle often characterised by yo-yo weight gain